Analyst Andrew Fein from H.C. Wainwright maintained a Buy rating on DBV Technologies SA – American and keeping the price target at $16.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Andrew Fein’s rating is based on the promising developments in DBV Technologies’ Viaskin Peanut program, particularly the VITESSE trial for peanut-allergic children aged 4-7 years. The trial, which is fully enrolled, uses a modified patch design that enhances the treatment’s effectiveness and is expected to meet FDA safety requirements without additional studies. If successful, this could lead to a Biologics License Application (BLA) submission in the first half of 2026, potentially unlocking significant capital and extending the company’s financial runway.
In addition, the ongoing progress in the toddlers’ group with the EPITOPE trial and the FDA’s formalization of an Accelerated Approval pathway further strengthen the company’s position. The COMFORT Toddlers study, which has begun screening participants, is expected to support a BLA submission in the second half of 2026. These strategic advancements and regulatory pathways for both the toddler and children age groups make DBV Technologies’ dual-path strategy for Viaskin Peanut a compelling investment opportunity.
According to TipRanks, Fein is a 4-star analyst with an average return of 8.4% and a 48.99% success rate. Fein covers the Healthcare sector, focusing on stocks such as Amylyx Pharmaceuticals Inc, Biogen, and Kymera Therapeutics.
In another report released today, LifeSci Capital also initiated coverage with a Buy rating on the stock with a $19.00 price target.